Oncternal Therapeutics (NASDAQ:ONCT) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note issued to investors on Monday. The firm issued a hold rating on the stock.

Oncternal Therapeutics Price Performance

NASDAQ:ONCT opened at $0.53 on Monday. The firm’s 50 day simple moving average is $0.53 and its 200 day simple moving average is $1.32. Oncternal Therapeutics has a one year low of $0.53 and a one year high of $10.00. The company has a market cap of $1.56 million, a PE ratio of -0.05 and a beta of 1.18.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.